Sun Pharmaceuticals announced its Q4FY23 results on May 26, reporting a consolidated net profit of ₹1,984 crore, compared to a net loss of ₹2,277 crore in the corresponding period last year. The pharma major’s revenue from operations during the January-March quarter came in at ₹10,930.6 crore, registering a growth of 15.7 per cent, compared to ₹9,446.8 crore in the year-ago period.
The company’s board recommended a final dividend of Rs. 4.00 per equity share of Re. l each, subject to the approval of shareholders. On the operating front, the company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) during the fourth quarter stood at ₹2,803 crore, reporting a rise of 19.7 per cent, compared to ₹2,340.4 crore in the same period last year.
The yearly rise in revenue was aided by double-digit growth in the specialty segment and robust sales in the domestic formulations business, along with some contribution from the sales of the generic Revlimid in the US market.
At 3:15 pm, shares of Sun Pharma were trading 3.02 per cent higher at ₹973.25 apiece on the BSE.
This copy is being updated
Know your inner investor
Do you have the nerves of steel or do you get insomniac over your investments? Let’s define your investment approach.
Take the test
Download The Mint News App to get Daily Market Updates.
More
Less
Updated: 26 May 2023, 03:14 PM IST
Article Source:Money Control
